Ban Zi Lian Indication 1. Clear away heat and toxic material, promote blood circul~ tion and remove blood stasis: For carbuncle, cellulitis, acute appendicitis, scorfula, snake bite, trauma and abdominal mass. Recently, usually applied for liver cancer, and also tumour of digestive tract, carcinoma of lung, cervix and breast, etc. 2. Clear away dampness-heat: For jaundice of dampnes~heat type, ascites, edema, leucorrhea of dampness-heat type and dysentery. 3. Eliminate the phlegm, relieve cough and dyspnea: For cough of lung-heat type with profuse expectoration and dyspnea.

Bai Hua She She Cao Pharmacological Action 1. Its components coumarins, triterpenes, poly?saccharide and "B" sitosterol inhibit the growth of sarcoma180 and cervix carcinoma14 in vitro. 2. Promoting white cell phagocytosis and humoral immunity.

Wu Wei Zi Astringent, anti-tussive, expectorant, anti-bacterial, hepatoprotective, adaptogenic, CNS stimulant/restorative, sedative, uterine stimulant, emmenagogue, cardiotonic, cholagogue, analgesic, regulates stomach acid secretion, urogenital testorative, aphrodisiac, regulates blood pressure, prevents excessive sweating, interferon inducent

Ku Shen A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B. Chen C, Guo SM, Liu B. Department of Infectious Diseases, 105th Hospital, HeFei, China. It has recently been shown that a Chinese traditional medicine, kurorinone, extracted from Sophora Flavescens Ait, possesses antiviral properties. We evaluated the efficacy and safety of kurorinone treatment in patients with chronic hepatitis B. Ninety-four patients with abnormal alanine transaminase (ALT) levels and hepatitis B e antigen (HBeAg) and/or hepatitis B virus (HBV) DNA-positivity were randomly assigned to receive either kurorinone 400 mg daily (45 patients) or 3 million units (MU) of interferon-alpha (IFN-alpha) (49 patients, daily for 1 month, every other day for 2 months) for 3 months. Patients were followed-up for 12 months. At baseline, both groups were comparable regarding age, gender and serological parameters. At the end of treatment, complete response (defined as ALT normalization and HBeAg and/or HBV DNA loss) occurred in 50% of the kurorinone group and in 61.3% of the IFN-alpha-treated group (P > NS). At the end of the 12-month follow-up period, a complete response (sustained response) occurred in 26.7-36.7% of kurorinone-treated patients with moderate or mild liver damage and in 44.4-46.7% of IFN-alpha-treated

• How to contact us
• How to order our products
• How to pay
• What's our service after sale